EPIGENETIC REGULATION OF F508DEL-CFTR IN CYSTIC FIBROSIS LUNG DISEASE

被引：0
|
作者：
Kumar, P. [1 ]
Frizzell, R. A. [2 ]
Pollard, H. [1 ]
Biswas, R. [1 ]
机构：
[1] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA
[2] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA USA
来源：
PEDIATRIC PULMONOLOGY | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
34
引用
收藏
页码：S226 / S226
页数：1
相关论文
共 50 条
  • [21] SFPQ rescues F508del-CFTR expression and function in cystic fibrosis bronchial epithelial cells
    Parameet Kumar
    Dharmendra Kumar Soni
    Chaitali Sen
    Mads B. Larsen
    Krystyna Mazan-Mamczarz
    Yulan Piao
    Supriyo De
    Myriam Gorospe
    Raymond A. Frizzell
    Roopa Biswas
    Scientific Reports, 11
  • [22] Calpain Inhibition Promotes the Rescue of F508del-CFTR in PBMC from Cystic Fibrosis Patients
    Averna, Monica
    Pedrazzi, Marco
    Minicucci, Laura
    De Tullio, Roberta
    Cresta, Federico
    Salamino, Franca
    Pontremoli, Sandro
    Melloni, Edon
    PLOS ONE, 2013, 8 (06):
  • [23] Enhanced F508del-CFTR Channel Activity Ameliorates Bone Pathology in Murine Cystic Fibrosis
    Le Henaff, Carole
    Hay, Eric
    Velard, Frederic
    Marty, Caroline
    Tabary, Olivier
    Marie, Pierre J.
    Jacquot, Jacky P.
    AMERICAN JOURNAL OF PATHOLOGY, 2014, 184 (04): : 1132 - 1141
  • [24] LNCRNA NEAT1 AND SFPQ REGULATE INFLAMMATION IN F508DEL-CFTR CYSTIC FIBROSIS LUNG EPITHELIAL CELLS
    Kumar, P.
    Kalurupalle, S.
    Frizzell, R. A.
    Pollard, H.
    Biswas, R.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 204 - 204
  • [25] INFECTIONS IN F508DEL-CFTR HOMOZYGOUS CYSTIC FIBROSIS PATIENTS TREATED WITH LUMACAFTOR/IVACAFTOR IN A NORTHERN ITALIAN CYSTIC FIBROSIS CENTER
    Colombo, C.
    Cariani, L.
    Sottotetti, S.
    Bisogno, A.
    Castcllazzi, L.
    Nazzari, E.
    Cigana, C.
    Bragonzi, A.
    PEDIATRIC PULMONOLOGY, 2018, 53 : 165 - 166
  • [26] miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells
    Kumar, P.
    Bhattacharyya, S.
    Peters, K. W.
    Glover, M. L.
    Sen, A.
    Cox, R. T.
    Kundu, S.
    Caohuy, H.
    Frizzell, R. A.
    Pollard, H. B.
    Biswas, R.
    GENE THERAPY, 2015, 22 (11) : 908 - 916
  • [27] Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
    Cholon, Deborah M.
    Esther, Charles R., Jr.
    Gentzsch, Martina
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2016, 1 (03): : 235 - 243
  • [28] Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial
    Sagel, Scott D.
    Khan, Umer
    Heltshe, Sonya L.
    Clancy, John P.
    Borowitz, Drucy
    Gelfond, Daniel
    Donaldson, Scott H.
    Moran, Antoinette
    Ratjen, Felix
    VanDalfsen, Jill M.
    Rowe, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (01) : 75 - 83
  • [29] SAFETY AND PHARMACOKINETICS OF N91115 IN PATIENTS WITH CYSTIC FIBROSIS HOMOZYGOUS FOR THE F508DEL-CFTR MUTATION
    Donaldson, S. H.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 293 - 293
  • [30] Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
    Amico, Giulia
    Brandas, Chiara
    Moran, Oscar
    Baroni, Debora
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (21)
12345